Konakion

Phytomenadione, the active ingredient in Konakion, is a vitamin K presented as a sterile solution for intravenous and oral use. It is used to treat vitamin K deficiency, to prevent and treat bleeding associated with anticoagulant therapy, and for neonatal prophylaxis of hemorrhagic disease of the newborn. GNH USA supplies Konakion as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Konakion is a vitamin K preparation that addresses disorders of coagulation and bleeding risk. - Vitamin K deficiency: restores normal clotting factor activity in patients with insufficient vitamin K levels. - Anticoagulant‑related bleeding: reverses excessive anticoagulation to control hemorrhage. - Neonatal hemorrhagic disease: provides prophylaxis to newborns to prevent bleeding complications.

Adverse reactions may occur with Konakion administration.

Common Side Effects: - Injection site pain or erythema: mild local discomfort at the site of administration. - Nausea or vomiting: transient gastrointestinal upset. - Headache: mild to moderate headache reported. - Diarrhea: occasional loose stools.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Severe bleeding: paradoxical hemorrhage despite therapy. - Thrombosis: formation of abnormal clots in vessels.

Use Konakion with careful clinical monitoring. - Monitor coagulation: check PT/INR values regularly during therapy. - Adjust in liver disease: dose may need modification in hepatic impairment. - Caution in newborns: use appropriate neonatal dosing and monitor bilirubin. - Avoid in known hypersensitivity: discontinue if allergic reaction occurs. - Store at ambient temperature: keep in original container, protect from light and moisture.

Konakion may interact with other medications affecting coagulation.

Major Interactions (Avoid): - Warfarin: may potentiate anticoagulant effect, increasing bleeding risk. - Other anticoagulants: concurrent use can exacerbate hemorrhage. - Broad‑spectrum antibiotics: may alter gut flora and affect vitamin K status.

Moderate Interactions (Monitor Closely): - Rifampin: may reduce phytomenadione levels, diminishing efficacy. - Phenobarbital: can increase metabolism, lowering therapeutic effect. - Cholestyramine: may bind vitamin K, decreasing absorption.